ClariTrial — AI Clinical Trial Intelligence

Explore/CRISPR gene editing clinical trials recruiting

Status

Phase

20 results for “CRISPR gene editing clinical trials recruiting”

Page 1 of 2

NCT07053462

Recruiting

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

Phase 1Phase 2End-Stage Renal DiseaseEnd Stage Renal Disease on DialysisEnd Stage Renal Disease With Renal Transplant

Ex Vivo CRISPR-Cas9 Gene Editing of Donor KidneyKidney Transplantation with Standard Care

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC90 participants1 site · ChinaCompletes Dec 2027

CT.gov Full analysis →

NCT06775561

Recruiting

Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes

N/ANeuromuscular DiseasesEye DiseasesGenetic Disease

PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.

IRCCS Azienda Ospedaliero-Universitaria di Bologna100 participants1 site · ItalyCompletes May 2025

CT.gov Full analysis →

NCT05740761

Recruiting

Gene Editing as a Therapeutic Approach for Rett Syndrome

N/ARett Syndrome

Gene editing in vitro

University of Siena40 participants1 site · ItalyCompletes Nov 2025

CT.gov Full analysis →

NCT06031727

Recruiting

CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Early Phase 1Neovascular Age-related Macular Degeneration(nAMD)

HG202

HuidaGene Therapeutics Co., Ltd.12 participants2 sites · ChinaCompletes Jun 2025

CT.gov Full analysis →

NCT06611436

Recruiting

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Phase 1Phase 2Hemophilia BHemophilia B, Moderately Severe or Severe

BE-101BE-101BE-101+1 more

Be Biopharma24 participants4 sites · United StatesCompletes Jul 2027

CT.gov Full analysis →

NCT07170254

Recruiting

A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL

N/AHigh-grade Squamous Intraepithelial Lesions (HSIL)

BD114VLP, or BD114BD114VLP or BD114 plus Gel

Shanghai BDgene Co., Ltd.12 participants1 site · ChinaCompletes Dec 2026

CT.gov Full analysis →

NCT06321289

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Phase 1Phase 2Non-hodgkin Lymphoma,B Cell

Allogeneic CD19-STAR T cellFludarabineCyclophosphamide

Chinese PLA General Hospital30 participants2 sites · ChinaCompletes Mar 2026

CT.gov Full analysis →

NCT05477563

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Phase 3Beta-ThalassemiaThalassemiaHematologic Diseases

CTX001

Vertex Pharmaceuticals Incorporated26 participants6 sites · United States, Germany, ItalyCompletes Jun 2027

CT.gov Full analysis →

NCT06465537

Recruiting

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

N/APrimary Open Angle Glaucoma

BD113vVLP

Shanghai BDgene Co., Ltd.9 participants1 site · ChinaCompletes Dec 2025

CT.gov Full analysis →

NCT06839235

Recruiting

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

Phase 1Phase 2Primary Hyperoxaluria Type 1 (PH1)

ABO-101

Arbor Biotechnologies23 participants7 sites · United States, France, GermanyCompletes Mar 2029

CT.gov Full analysis →

NCT06492304

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Phase 1Phase 2T Cell LymphomaB Cell LymphomaAcute Myeloid Leukemia

CTX131

CRISPR Therapeutics290 participants7 sites · United States, AustraliaCompletes May 2030

CT.gov Full analysis →

NCT07099443

Recruiting

Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL

N/AChronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia

Non-Interventional Sample Collection and Analysis

Nantes University Hospital60 participants14 sites · FranceCompletes Sep 2039

CT.gov Full analysis →

NCT05805007

Recruiting

Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

Early Phase 1Retinitis Pigmentosa

ZVS203e

Peking University Third Hospital9 participants1 site · ChinaCompletes Apr 2026

CT.gov Full analysis →

NCT06615206

Recruiting

A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

N/AMECP2 Duplication Syndrome

HG204

HuidaGene Therapeutics Co., Ltd.6 participants1 site · ChinaCompletes Oct 2026

CT.gov Full analysis →

NCT06014073

Recruiting

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Phase 1Phase 2Non Hodgkin's Lymphoma

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)FludarabineCyclophosphamide

Chinese PLA General Hospital30 participants3 sites · ChinaCompletes Sep 2025

CT.gov Full analysis →

1–15 of 20

Explore/CRISPR gene editing clinical trials recruiting

Status

Phase

20 results for “CRISPR gene editing clinical trials recruiting”

Page 1 of 2

NCT07053462

Recruiting

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

Phase 1Phase 2End-Stage Renal DiseaseEnd Stage Renal Disease on DialysisEnd Stage Renal Disease With Renal Transplant

Ex Vivo CRISPR-Cas9 Gene Editing of Donor KidneyKidney Transplantation with Standard Care

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC90 participants1 site · ChinaCompletes Dec 2027

CT.gov Full analysis →

NCT06775561

Recruiting

Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes

N/ANeuromuscular DiseasesEye DiseasesGenetic Disease

PARADIGM study aims to streamline the process from genomic characterization of RGD patients with ED/NMD to identification of the suitable personalized therapy.

IRCCS Azienda Ospedaliero-Universitaria di Bologna100 participants1 site · ItalyCompletes May 2025

CT.gov Full analysis →

NCT05740761

Recruiting

Gene Editing as a Therapeutic Approach for Rett Syndrome

N/ARett Syndrome

Gene editing in vitro

University of Siena40 participants1 site · ItalyCompletes Nov 2025

CT.gov Full analysis →

NCT06031727

Recruiting

CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

Early Phase 1Neovascular Age-related Macular Degeneration(nAMD)

HG202

HuidaGene Therapeutics Co., Ltd.12 participants2 sites · ChinaCompletes Jun 2025

CT.gov Full analysis →

NCT06611436

Recruiting

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

Phase 1Phase 2Hemophilia BHemophilia B, Moderately Severe or Severe

BE-101BE-101BE-101+1 more

Be Biopharma24 participants4 sites · United StatesCompletes Jul 2027

CT.gov Full analysis →

NCT07170254

Recruiting

A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL

N/AHigh-grade Squamous Intraepithelial Lesions (HSIL)

BD114VLP, or BD114BD114VLP or BD114 plus Gel

Shanghai BDgene Co., Ltd.12 participants1 site · ChinaCompletes Dec 2026

CT.gov Full analysis →

NCT06321289

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Phase 1Phase 2Non-hodgkin Lymphoma,B Cell

Allogeneic CD19-STAR T cellFludarabineCyclophosphamide

Chinese PLA General Hospital30 participants2 sites · ChinaCompletes Mar 2026

CT.gov Full analysis →

NCT05477563

Recruiting

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Phase 3Beta-ThalassemiaThalassemiaHematologic Diseases

CTX001

Vertex Pharmaceuticals Incorporated26 participants6 sites · United States, Germany, ItalyCompletes Jun 2027

CT.gov Full analysis →

NCT06465537

Recruiting

CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

N/APrimary Open Angle Glaucoma

BD113vVLP

Shanghai BDgene Co., Ltd.9 participants1 site · ChinaCompletes Dec 2025

CT.gov Full analysis →

NCT06839235

Recruiting

Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)

Phase 1Phase 2Primary Hyperoxaluria Type 1 (PH1)

ABO-101

Arbor Biotechnologies23 participants7 sites · United States, France, GermanyCompletes Mar 2029

CT.gov Full analysis →

NCT06492304

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Phase 1Phase 2T Cell LymphomaB Cell LymphomaAcute Myeloid Leukemia

CTX131

CRISPR Therapeutics290 participants7 sites · United States, AustraliaCompletes May 2030

CT.gov Full analysis →

NCT07099443

Recruiting

Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL

N/AChronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic Leukemia

Non-Interventional Sample Collection and Analysis

Nantes University Hospital60 participants14 sites · FranceCompletes Sep 2039

CT.gov Full analysis →

NCT05805007

Recruiting

Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa

Early Phase 1Retinitis Pigmentosa

ZVS203e

Peking University Third Hospital9 participants1 site · ChinaCompletes Apr 2026

CT.gov Full analysis →

NCT06615206

Recruiting

A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)

N/AMECP2 Duplication Syndrome

HG204

HuidaGene Therapeutics Co., Ltd.6 participants1 site · ChinaCompletes Oct 2026

CT.gov Full analysis →

NCT06014073

Recruiting

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Phase 1Phase 2Non Hodgkin's Lymphoma

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)FludarabineCyclophosphamide

Chinese PLA General Hospital30 participants3 sites · ChinaCompletes Sep 2025

CT.gov Full analysis →

1–15 of 20